

# EVALUATION OF STAPHYLOCOCCAL ACTIVITY OF *GARCINIA KOLA* ALMONDS

## Abstract

The emergence of infectious diseases, particularly staphylococcal infections, treatment failures and the more high cost of treatment of infections caused by resistant staphylococci called to find other care alternatives. This study was initiated to evaluate the antibacterial activity of the aqueous extract from *Garcinia kola* almonds on the *in vitro* growth of *Staphylococcus aureus* strains. The methods of diffusion in agar and liquid media were used for susceptibility testing and MIC and MBC determination. The tests were performed on four strains of *S. aureus* and one reference strain. The minimum inhibitory concentrations of the extracts ranged from 3.12 mg/mL and 12.5 mg/mL and the minimum bactericidal concentrations between 6.25 mg/mL and 25 mg/mL. The lowest value of MIC and MBC was observed with *S. aureus* ATCC 29213 while the greatest value of these same parameters was obtained on *S. aureus* 993C/18 and *S. aureus* 1075C/18. The aqueous almonds extract of *Garcinia kola* had a bactericidal activity on all the strains of *S. aureus* studied. This could justify the use of *Garcinia kola* almonds in the treatment of various diseases in traditional society.

**Key words:** *Garcinia kola*, aqueous extract, *Staphylococcus aureus*, MIC, MB

## INTRODUCTION

Infectious diseases are nowadays the cause of nearly 17 million deaths a year and are a major preoccupation for health workers (Simpore *et al.*, 2006). In developing countries, they account for 45% of deaths, of which 14.2% in Côte d'Ivoire (Walsh, 2003). These infections include severe skin diseases and mucous membranes such as endocarditis and sepsis caused by bacteria of *Staphylococcus* genus (Duval 1989). The prevalence of nosocomial and community-acquired staphylococcal infections is increasing steadily. However, the treatment of these infections has become increasingly difficult because of the emergence of multi-resistant strains (Mougeot *et al.*, 2001). In addition, *Staphylococcus aureus* is currently one of the leading causes of nosocomial infection worldwide because 10-50% of *S. aureus* strains isolated in hospitals are resistant to meticillin, including vancomycin, the glycopeptide used against methicillin-resistant strains (Kopp *et al.*, 2004). The ability of *S. aureus* to develop multiple resistance to antibiotics increasingly limits therapeutic possibilities and thus poses a serious public health problem (Accarias, 2014). Otherwise, conventional antibiotics used against microbial diseases are expensive, difficult to access by poor people and are still not

34 effective and appropriate (Bennet *et al.*, 2000). They sometimes have high side effects on  
35 human health whose targets are the heart, liver, kidneys, blood (Odds *et al.*, 2003). To fight  
36 against pathogenic microorganisms, the search for new natural phytomedicines has become  
37 an emergency for ethnopharmacologists, botanists, pharmacists and microbiologists (Kavitha  
38 and Padma, 2008). Efforts in this area have focused on plants because of their multiple use  
39 by a large portion of the world's population (Akinnibosun *et al.*, 2008). It is within this  
40 framework, that we are interested in *Garcinia kola* whose study will contribute to the  
41 valorization of the Ivorian medicinal plants. This plant is used by people as an aphrodisiac  
42 and also in the traditional treatment of gastritis, stomach upset and many other pathologies  
43 (Odebunmi *et al.*, 2009).

## 44 I-Material and methods

### 45 1.1-Plant material

46 The plant material used consists of *Garcinia kola* almond powder. These almonds were  
47 harvested in August, 2018 on the market of ELIBOU (located on the North Highway about  
48 79 kilometers from Abidjan). The almonds have been grated and dried out of the sun at  
49 laboratory temperature (25 to 30 ° C) for 15 days. Once dried, they have been reduced to a  
50 fine powder using a GM 300 type Retsch grinder. The powders obtained were stored in  
51 sealed flasks. These powder were used for the preparation of plant extracts.

### 52 1.2-Bacterial material

53 Several strains of *S. aureus* were used including one reference strain and four others of  
54 different profile provided by the Bio Bank of the Institut Pasteur Côte d'Ivoire (Table I).

55 Table I: Profile of the bacteria tested.

Strains	Profile
<i>S. aureus</i> ATCC 29213	$\beta$ -lactam reference strains
<i>S. aureus</i> 993C/18	$\beta$ -lactam resistant strain
<i>S. aureus</i> 1074C/18	Methicellin resistant strain
<i>S. aureus</i> 1075C/18	Wild strain
<i>S. aureus</i> 1076C/18	Wild strain with $\beta$ -lactam

56

## 57 2-Methods

## 58 **2.1-Preparation of the aqueous extract**

59 It was carried out according to the method described by **Ackah *et al.* (2008)**. The powder  
60 (100 g) of *Garcinia kola* was dissolved in 1000 ml of distilled water and then homogenized in  
61 a Blender at room temperature. The homogenate obtained was first wrung out in a square of  
62 white fabric. Then, doubly filtered on hydrophilic cotton and once on whatman paper 3 mm.  
63 The filtrate obtained was dried in an oven at 50 ° C. for 48 hours. The mass of extract  
64 obtained was stored in sterile, clean, dry flasks then kept out of from heat and moisture. The  
65 percentage of the extraction yield was calculated according to the following formula:

66

## 67 **2.2-Antibacterial tests**

### 68 **2.2.1-Preparation and Seeding of the Concentration Range**

69 The concentration range of the plant extract was prepared in seven test tubes numbered from  
70 1 to 7 by the double dilution method according to a geometric progression of 1/2 reason. In a  
71 series of eight hemolysis tubes numbered C1 to C8, 1mL of pure inoculum was introduced.  
72 Then, 1mL of plant extract was added to the tubes according to the prepared concentration  
73 range. This distribution of plant extract was made so that 1mL of 200 mg/mL plant extract  
74 was transferred into the C1 tube. Tube C2 received 1 mL of 100 mg/mL and so on until tube  
75 C7 received 1mL of the 3.125 mg/mL solution. The C8 tube received instead of the plant  
76 extract, 1 ml of sterile BMH which was used as a growth control. As a result of the  
77 volume/volume dilution achieved, the concentration in the tubes was reduced by half. These  
78 tubes were incubated at 37°C for 24 hours. (**Toty *et al.*, 2013**).

79

### 80 **2.2.2-Preparation of the bacterial inoculum**

81 The bacterial inoculum was prepared according to the method described by (Toty *et al.*,  
82 2013). The bacterial inoculum was prepared from an isolated 18-hour colony in 10 mL Mueller  
83 Hinton broth (MHB) and incubated for 3 to 5 hours at 37°C to obtain a pre-culture. A volume of 0.1  
84 mL was collected and added to 10 mL of BMH twice concentrated. This bacterial suspension is  
85 evaluated at about 10<sup>6</sup> cells/mL and constitutes the 10<sup>0</sup> dilution or pure inoculum.

86

### 87 **2.2.3-Sensitivity test**

88 The agar diffusion technique was used to study the sensitivity tests. Mueller Hinton medium,  
89 poured and dried in a petri dish, was flooded with 3 mL of inoculum. Then, using a sterile  
90 die, wells about 6 mm in diameter were drilled into the agar. Each well received 80  $\mu$ L of the  
91 test substance at a concentration of 100 mg/mL. The Petri dishes were incubated at 37°C for  
92 24 hours, after 30 minutes of diffusion at laboratory temperature. The presence or absence of  
93 an inhibition zone was observed and the inhibition diameter was measured. Oxacillin was  
94 used as a control. The interpretation was made according to **Ponce *et al.* (2003)**.

95

### 96 **2.2.4-Antibacterial parameters MIC and MBC.**

97 Minimal Inhibitory Concentration (MIC) was the lowest concentration of the plant extract for  
98 which there is no visible growth to the naked eye after 24 hours of incubation. His  
99 determination was made by observation of the disorder induced by the growth of the germs  
100 present in each tube. From the MIC, the smallest concentration that allows only 0.01% of  
101 bacteria in suspension to survive in 24 hours corresponds to CMB. It is determined by  
102 spreading on a solid medium of 2  $\mu$ L of the contents of each tube of concentration greater  
103 than or equal to the MIC (**Soussy *et al.*, 2012**).

104

### 105 **2.3-Statistical Analyzes**

106 All results were repeated three times. The data was processed using the Graph Pad Prism 5.0  
107 software (Microsoft, USA). Statistical analysis of the results was performed using Anova  
108 One-Way. The value of the averages is accompanied by the standard error on the mean (mean  
109  $\pm$  SEM).

110

## 111 **3-Results**

### 112 **3.1-Extraction**

113 The yield, appearance and color of the aqueous extract of *Garcinia kola* almonds are shown  
114 in Table II. This extract in powder form, of brown color obtained a yield of 6.36%.

115 Table II: Color, appearance and yield of the aqueous extract of *Garcinia kola* (clusiaceae).

	Characteristics		
	Color	Appearance	Yield (%)
aqueous extract	brown	Powder (not very pasty)	6,36 %

116

117

### 118 3.2-Antibacterial effects

#### 119 3.2.1-Sensitivity test

120 The values of the inhibition diameters of the *G. kola* extract and of the reference molecule are  
 121 shown in Tables III and IV. The plant extract recorded inhibition diameters ranging from  
 122 10.00 ± 0.00 mm to 16.33 ± 0.58 mm. The largest diameter values (16.33 ± 0.58 mm, 15.66 ±  
 123 0.58 mm and 15.33 ± 0.58 mm) were obtained with *S. aureus* 993C / 18, *S. aureus* ATCC  
 124 29213 and *S. aureus* 1074C / 18 respectively, while *S. aureus* 1076C / 18 and *S. aureus*  
 125 1075C / 18 exhibited smaller values (13.33 ± 1.53 mm and 13.00 ± 2.00 mm). These  
 126 diameters remain lower than those obtained by the reference molecule (oxacillin).

127

128

129 **Table III: Inhibition diameters (mm) induced by the aqueous extract**

Strains	Concentrations (mg/mL)							
	200	100	50	25	12,5	6,25	3,12	1,56
<i>S. aureus</i> ATCC 29213	15,66 ± 0,58	13,00 ± 0,00	11,67 ± 0,58	10,00 ± 0,00	6,00 ± 0,00	6,00 ± 0,00	6,00 ± 0,00	6,00 ± 0,00
<i>S. aureus</i> 993C/18	16,33 ± 0,58	14,33 ± 0,58	12,00 ± 0,00	11,00 ± 0,00	6,00 ± 0,00	6,00 ± 0,00	6,00 ± 0,00	6,00 ± 0,00

<i>S. aureus</i> 1074C/18	15,33 ± 0,58	12,67 ± 1,15	11,00 ± 1,00	10,00 ± 1,00	6,00 ± 0,00	6,00 ± 0,00	6,00 ± 0,00	6,00 ± 0,00
<i>S. aureus</i> 1075C/18	13,00 ± 2,00	11,67 ± 1,53	10,67 ± 0,53	6,00 ± 0,00	6,00 ± 0,00	6,00 ± 0,00	6,00 ± 0,00	6,00 ± 0,00
<i>S. aureus</i> 1076C/18	13,33 ± 1,53	12,00 ± 1,00	11,00 ± 1,00	10,00 ± 0,00	6,00 ± 0,00	6,00 ± 0,00	6,00 ± 0,00	6,00 ± 0,00

130 6,00±0,00: corresponds to the wells diameters

131

132

133

UNDER PEER REVIEW

134

135 **Table IV: Inhibition diameters (mm) induced by the antibiotic (Oxacillin)**

Strains	Concentrations (mg/mL)														
	62,50	31,25	15,63	7,81	3,91	1,95	0,98	0,49	0,24	0,12	0,061	0,031	0,016	0,008	0,004
<i>S. aureus</i> ATCC 29213	>52	>52	>52	>52	>52	>52	>52	>52	34	28	21	21	18	6,00	6,00
									± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00
<i>S. aureus</i> 993C/18	50	49	48	46	43	40	38	36	32	26	25	22	19	6,00	6,00
	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00
<i>S. aureus</i> 1074C/18	39	39	35	35	33	32	30	28	28	26	22	18	6,00	6,00	6,00
	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00
<i>S. aureus</i> 1075C/18	52	51	46	45	43	40	38	35	30	28	24	21	18	6,00	6,00
	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00
<i>S. aureus</i> 1076C/18	46	43	40	38	35	34	33	28	25	22	16	6,00	6,00	6,00	6,00
	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00

136 6,00±0,00: corresponds to the wells diameters

137 **3.2.2-Determination of antibacterial activity**

138 The results of the antibacterial parameters obtained are mentioned in Tables V and VI.  
 139 Analysis of the results of the tables revealed that MICs obtained on *S. aureus* strains ranged  
 140 from  $3.12 \pm 0.00$  mg / mL to  $12.50 \pm 0.00$  mg / mL. The lowest MIC value was observed for  
 141 *S. aureus* ATCC 29213 ( $3.12 \pm 0.00$  mg / mL) and the highest value was obtained with *S.*  
 142 *aureus* 993C / 18 and *S. aureus* 1075C / 18 ( $12.5 \pm 0.00$  mg / mL). As for MBC, the recorded  
 143 values ranged from  $6.25 \pm 00$  to  $25 \pm 00$  mg / mL. This made it possible to determine the  
 144 MBC / MIC ratio. The aqueous extract of *G. kola* obtained MBC / MIC  $\leq 2$  on all the strains  
 145 of *S. aureus* (Table V). However, this ratio varied from 2 to 4 with the reference molecule  
 146 Table VI.

147

148 **Table V: Antibacterial Parameters of the Aqueous Extract**

Strains	Antibacterial parameters (mg/mL)		Ratio efficacy (MBC / MIC)	Effect
	MIC	MBC		
<i>S. aureus</i> ATCC 29213	$3,12 \pm 0,00$	$6,25 \pm 0,00$	2	Bactericidal
<i>S. aureus</i> 993C/18	$12,5 \pm 0,00$	$25 \pm 0,00$	2	Bactericidal
<i>S. aureus</i> 1074C/18	$6,25 \pm 0,00$	$12,5 \pm 0,00$	2	Bactericidal
<i>S. aureus</i> 1075C/18	$12,5 \pm 0,00$	$25 \pm 0,00$	2	Bactericidal
<i>S. aureus</i> 1076C/18	$6,25 \pm 0,00$	$6,25 \pm 0,00$	1	Bactericidal

149

150

151

152

153

154

155 **Table VI: Antibacterial parameters of the antibiotic (oxacillin).**

Strains	antibactericidal parameters (mg/mL)		Ratio efficacy (MBC / MIC)	Effect
	MIC	MBC		
<i>S. aureus</i> ATCC 29213	15,63± 0,00	31,25± 0,00	2	Bactericidal
<i>S. aureus</i> 993C/18	7,81± 0,00	31,25± 0,00	4	Bacteriostatic
<i>S. aureus</i> 1074C/18	7,81± 0,00	31,25± 0,00	4	Bacteriostatic
<i>S. aureus</i> 1075C/18	15,63± 0,00	62,5± 0,00	4	Bacteriostatic
<i>S. aureus</i> 1076C/18	3,91± 0,00	7,81± 0,00	2	Bactericidal

156

157

158 **4-Discussion**

159 The present study was initiated with the aim of evaluating the antibacterial activity of the  
160 aqueous extract of *Garcinia kola* almonds on the in vitro growth of *Staphylococcus aureus*  
161 strains. During this study, distilled water was used as an extraction solvent. The extraction  
162 yield (6.36%) obtained from our study is less than 8.8% recorded by **Yété et al. (2015)** during  
163 the aqueous extraction of almonds from this same plant. The observed variation in yield  
164 could be related to several parameters. Indeed, several authors have reported that the  
165 extraction yield may depend on several factors such as the time of harvest of the plant, the  
166 plant age, the drying procedure, the solvent, the pH, the temperature, the extraction time and  
167 sample composition (**Quy et al., (2014), Stalikas (2007)**). With regard to the antibacterial  
168 effects, the results obtained show that the aqueous extract of *G. kola* almonds has an  
169 inhibitory activity against the in vitro growth of staphylococci with a different degree related  
170 to the profile of the strains. All strains of *S. aureus* studied were sensitive to the aqueous *G.*  
171 *kola* extract. These results are similar to those obtained by **Akerele et al. (2008)**. These

172 authors recorded inhibition diameters of  $20 \pm 2.4$  mm on *S. aureus* strains. Overall, *S. aureus*  
173 993C / 18 was more sensitive to the extract studied. However, the inhibition diameters  
174 induced by the aqueous extract remain lower than those of the reference antibiotic. Regarding  
175 to the measurement of antibacterial activity, it should be recalled that when the MBC / MIC  
176 efficacy ratio of an antibacterial substance is less than or equal to two ( $\leq 2$ ), the latter is  
177 described as a bactericidal substance. If the MBC / MIC ratio is greater than two ( $> 2$ ), then it  
178 is called bacteriostatic (**Fauchere and Avril, 2002**). In view of this principle, the aqueous  
179 extract of *G. kola* has a bactericidal effect on all the strains studied. Our results corroborate  
180 those of **Morabandza et al. (2014)**. These authors have indicated that the aqueous extract of  
181 *G. kola* mesocarp has a bactericidal effect on *S. aureus* strains. Similar results were also  
182 obtained in the *Harungana madagascariensis* study (**Toty et al., 2013**). However, the  
183 comparison of the performance of our extract with that of the control (oxacillin), indicates  
184 that the aqueous extract is bactericidal on all strains of *S. aureus* tested while oxacillin is  
185 bactericidal on *S. aureus* ATCC 29213 and *S. aureus* 1076C / 18 but bacteriostatic on the  
186 other strains. This indicates that the aqueous extract of *G. kola* has better antibacterial activity  
187 than oxacillin. This bactericidal effect of the aqueous extract of *G. kola* could be explained by  
188 the presence of secondary metabolites found therein namely alkaloids, anthraquinones,  
189 flavonoids, saponosides, tannins, terpenes and steroids (**Morabandza et al. 2013**). Studies  
190 have shown that flavonoids are good inhibitors of the sortases, enzymes found in the  
191 cytoplasmic membrane of Gram-positive bacteria that catalyze all surface proteins (adhesins  
192 and internalins) (**Cushnie and Lamb, 2011**). According to these authors, epigallocatechin  
193 prevents the secretion of coagulase and *S. aureus*  $\alpha$ -toxin. Flavonoids also inhibit the release  
194 of virulence factors of this bacterium (**Ghedadba et al., 2015**). The synergistic actions at  
195 various levels of the secondary metabolites would be at the base of the antibacterial activity  
196 of the extract. The results obtained during this study have justified the use of this plant in  
197 traditional medicine.

198

## 199 **Conclusion**

200 The in-vitro study of the aqueous extract of almonds of *G. kola* made it possible to highlight  
201 the antibacterial properties of this plant on the growth of the staphylococcal germs studied.  
202 The results obtained reveal the presence of antibacterial active principles in the aqueous  
203 extract of *G. kola* almonds. The results showed a bactericidal effect of the extract studied on

204 these strains of *S. aureus*. This bactericidal effect observed is dose dependent. The sensitivity  
205 of staphylococcal strains to the aqueous extract of *G. kola* almonds is of great importance in  
206 the treatment of pathologies associated with them. The present results justify certain  
207 ethnopharmacological uses. They demonstrate that this plant can be used to treat infectious  
208 diseases of staphylococcal origin. In view of the results, it would be interesting to undertake  
209 studies to evaluate the toxicity and then purify the extract of this plant to consider the  
210 development of improved traditional medicines.

211

#### 212 **Bibliographical references:**

213 **Accarias S.** Impact du phénotype des macrophages résidents sur la nature de la réponse  
214 inflammatoire précoce lors d'une infection par *Staphylococcus aureus*. Thèse de Doctorat,  
215 Université de Toulouse, France, **2014**.

216 **Ackah J. A. A. B., Kra A. K. M., Zirihi G. N. & Guédé-Guina F.** Evaluation de l'activité  
217 antifongique de tekam, un extrait de plante, sur la croissance *in vitro* de *candida albicans*.  
218 *Revue Ivoirienne Sciences Technologiques*, **2008**; 11: 119-129.

219 **Akerele J. O., Obasuyi O., Ebomoyi M. I., Oboh I. E. & Uwumarongie O. H.**  
220 Antimicrobial activity of the ethanol extract and fractions of the seeds of *Garcinia kola*  
221 Heckel (Guttiferae). *African Journal of Biotechnology*, **2008**; 7: 169-172.

222 **Akinnibosun H. A., Akinnibosun F. I. & German B. E.** Antibacterial activity of aqueous  
223 and ethanolic leaf extracts of *Peperomia pellucida* (L.) H. B. & K. (*piperaceae*) on three  
224 gram-negative bacteria isolates. *Science World Journal*, **2008**; 3: 33-36.

225 **Bennet D. M., Bhandol P. and Leitch I. J.** Nuclear DNA amounts in  
226 angiosperms and their modern Uses 807 new estimates. *Annals of Botany*, **2000**; 86: 859-909.

227 **Cushnie T.P.T. & Lamb A;J.** Recent advances in understanding the antibacterial properties  
228 of flavonoïds. *Internat J Antimicrob Agents*, **2011**; 1-9

229

230 **Duval J.** Evolution des résistances. *In*: LE MINOIR L et VERON M, eds. Bactériologie  
231 médicale. Flammarion Paris (France), **1989**.

232 **Fauchere J. L. & Avril J. L.** Bactériologie Générale et Médicale, Edition Ellipses, Paris  
233 (France), **2002**.  
234

235 **Ghedadba N. Hambaba L. Ayachi A. Aberkane M. C. Bousselfela H. Oueld-Mokhtar S.**  
236 **M.** Polyphénols totaux, activités antioxydante et antimicrobienne des extraits des feuilles de  
237 *Marrubium deserti* de Noé. *Phytothérapie*, **2015**; 1-12.  
238

239 **Kavitha D. & Padma P. R.** Biotherapeutic potential of flower and bark extracts of  
240 *Couroupita guianensis* Aubl. *Plant Archives*, **2008**; 8: 569-771.

241 **Kopp B. J., Nix D. E. & Armstrong E. P.** Clinical and economic analysis of methicillin  
242 susceptible and -resistant *S. aureus* infections. *Annals of Pharmacotherapy*, **2004**; 38: 1377-  
243 1382.

244 **Morabandza C. J., Okemy A. N., Ongoka R. P., Okiemy-Akieli M. G., Attibayeba A. &**  
245 **Abena A. A.** Effets antimicrobiens, anti-inflammatoires et antioxydants du mésocarpe de  
246 *Garcinia kola* Heckel (Clusiaceae). *Phytothérapie*, **2014**; 12: 164-169.

247 **Mougeot C., Guillaumat-Taillet .Y. & Libert J. M.** *Staphylococcus aureus*: nouvelle  
248 détection de la résistance intrinsèque par la méthode de diffusion. *Pathologie biologique*, **2001**;  
249 49: 199-204.

250 **Odds F.C., Brown A.J.P., Gow N.A.R.** Antifungal agents: Mechanisms of action. *Trends in*  
251 *Microbiology*, **2003**; 11: 272-279.

252 **Odebunmi E. O., Oluwaniyi O. O., Awolola G. V. & Adediji O. D.** Proximate and  
253 nutritional composition of kola nut (*Cola nitida*), bitter cola (*Garcinia kola*) and alligator  
254 pepper (*Aframomum melegueta*). *African Journal of Biotechnology*, **2009**; 8: 308-310.

255 **Ponce A. G., Fritz R., Del Alle C. & Roura S.I.** Antimicrobial activity of essential oil on  
256 the native microflora of organic Swiss chard. *Lebensmittel-Wissenschaft und Technologie*,  
257 **2003**; 36: 679-684.

258 **Quy Diem Do., Angkawijay A. E., Tran-Nguyen P. L., Huynh L. H., Soetaredjo F. E.,**  
259 **Isadj S., & Ju Y-H.** Effect of extraction solvent on total phenol content, total flavonoids  
260 content, and antioxidant activity of *Limnophila aromatica*. *Journal of Food and Drug*  
261 *analysis*, **2014**; 22: 296-302.

262 **Simporé J., Pietra V., Savadogo A., Pignatelli S., Nikiema J. B., Nadembega W. M.,**  
263 **Yara J., Zoungrana N., Bakouan D., Colizzi V., Castelli F. & Musumeci S.** Reduction of  
264 mother in to child transmission of HIV at Saint Camille Medical Centre in Burkina Faso.  
265 *Journal of Medical virology*, **2006**; 78: 148-152.

266 **Stalikas C. D.** Extraction, separation, and detection methods for phenolic acids and  
267 flavonoids. *Journal of Separation Science*, **2007**; 30: 3268-3295.

268 **Soussy C. J., Cavallo J. D., Courcol R., Drugeon H., Fabre R. & Jarlier V.** Sensibilité  
269 aux antibiotiques des souches d'*Escherichia coli* isolées en 1998 et 1999: résultats d'une  
270 enquête multicentrique française. *Médecine et Maladies Infectieuses*, **2000**; 30: 650-656.

271

272 **Toty A. A., Guessennd N., Bahi C., Kra A. M., Otokore D. A. & Dosso M.** Évaluation *in-*  
273 *vitro* de l'activité antibactérienne de l'extrait aqueux de l'écorce de tronc de *Harungana*  
274 *madagascariensis* sur la croissance de souches multi-résistantes. *Bulletin de la Société Royale*  
275 *des Sciences de Liège*, **2013**; 82: 12-21

276

277 **Walsh C.** Antibiotics: actions, origins, resistance. *American Society for Microbiology*,  
278 Washington, D. C (USA), **2003**.

279 **Yété P., Togbé A., Koudoro Y., Agbangnan P., Ndahischimiye V., Djènantin T. S.,**  
280 **Wotto D, Azandégbé E. C. & Sohounhloue D.** Etude comparative des Composés  
281 phénoliques et activité antiradicalaire des extraits des Graines de *Garcinia kola* (Guttiféreae)  
282 et de *Cucumeropsis edulis* (cucurbitacéae) du Bénin. *International Journal of Innovation and*  
283 *Scientific Research*, **2015**; 15: 217-227.

284